Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
← catalyst calendarNCT06072612 · readout ≤ 499 d
Sponsored by BriaCell Therapeutics Corporation (industry) · BCTX — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
404estimated
Sites
79
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-05 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Metastatic Breast Cancer
- Breast Neoplasm
- Breast Cancer Metastatic
- End Stage Cancer
Interventions
- Biological: SV-BR-1-GM — also filed as Part of the Bria-IMT regimen
- Drug: Cyclophosphamide
- Drug: Interferon infiltration of the inoculation site
- Drug: Retifanlimab
- Drug: Treatment of Physician's Choice
Primary outcome
what the primary-completion date above is the date OFOverall Survival
measured Up to 60 months
Permalink · BCTX's whole pipeline · Catalyst calendar · Every registered study · What changed